{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T10:23:26Z","timestamp":1792491806388,"version":"4.5.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Global phase III clinical trials have shown superior hypoglycemic efficacy to insulin and other oral hypoglycemic agents. However, there is a scarcity of real-world data comparing different glucagon-like peptide 1 receptor agonist (GLP-1RA) directly. This study aimed to assess the safety and effectiveness of various GLP-1RA in treating type 2 diabetes mellitus (T2DM) in a real-world clinical setting and identify predictive factors for favorable treatment outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective, single-center, real-world study. The changes in HbA1c, fasting plasma glucose (FPG), body weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), and the percentage of participants who achieved HbA1c of &amp;lt;7%, 7%-8%, and \u2265 8% after GLP-1RA treatment was analyzed. The clinical factors that affect the effectiveness of GLP-1RA were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At baseline, the 249 participants had a mean baseline HbA1c of 8.7 \u00b1 1.1%. After at least three months of follow-up, the change in HbA1c was -0.89 \u00b1 1.3% from baseline. Dulaglutide exerted a more significant hypoglycemic effect than immediate-release exenatide. The percentage of participants who achieved HbA1c&amp;lt;7% was substantial, from 6.0% at baseline to 28.9%. Average body weight decreased by 2.02 \u00b1 3.8 kg compared to baseline. After GLP-1RA treatment, the reduction in SBP was 2.4 \u00b1 7.1 mmHg from baseline. A shorter duration of diabetes and a higher baseline HbA1c level were more likely to achieve a good response in blood glucose reduction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study provided real-world evidence showing that GLP-1RA significantly improved HbA1c, body weight, and SBP. The results can inform the decision-making about GLP-1RA treatment in daily clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1347684","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T08:47:00Z","timestamp":1709887620000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study"],"prefix":"10.3389","volume":"15","author":[{"given":"Yan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Sheng","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Ting","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Jun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.877797","article-title":"New hypoglycemic drugs: combination drugs and targets discovery","volume":"13","author":"Ni","year":"2022","journal-title":"Front Pharmacol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2623","article-title":"Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a GLP-1RA or to basal insulin plus an SGLT2 inhibitor: BEYOND, a randomized, pragmatic trial","volume":"44","author":"Giugliano","year":"2021","journal-title":"Diabetes Care"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-Weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1615712","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"376","author":"Marso","year":"2017","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0166-0","article-title":"Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States","volume":"31","author":"Johnston","year":"2014","journal-title":"Adv Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1432","article-title":"Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: A systematic review and network meta-analysis","volume":"164","author":"Zaccardi","year":"2016","journal-title":"Ann Internal Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-018-0038-0","article-title":"Clinical pharmacology of glucagon-like peptide-1 receptor agonists","volume":"17","author":"Sfairopoulos","year":"2018","journal-title":"Hormones"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"Dungan","year":"2014","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"investigators S: Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051718","article-title":"Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE initiative","volume":"143","author":"Franklin","year":"2021","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112338-20220513-00408","article-title":": [Real-world evidence and randomized controlled trials: the initiation, implementation, progress interpretation and revelation of RCT DUPLICATE (part 1)]","volume":"43","author":"Shi","year":"2022","journal-title":"Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112338-20220513-00409","article-title":"[Real-world evidence and randomized controlled trials: the initiation, implementation, progress interpretation and revelation of RCT DUPLICATE (part 2)]","volume":"43","author":"Shi","year":"2022","journal-title":"Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.2337\/dc18-S006","article-title":"6. Glycemic targets: standards of medical care in diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01313-0","article-title":"Effectiveness and safety of once-weekly semaglutide in Japanese patients with type 2 diabetes in treatment intensification: A retrospective observational single-center study","volume":"13","author":"Yamada","year":"2022","journal-title":"Diabetes Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/304368a0","article-title":"Exon duplication and divergence in the human preproglucagon gene","volume":"304","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.1.124","article-title":"Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor","volume":"52","author":"Buteau","year":"2003","journal-title":"Diabetes"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051238","article-title":"Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells","volume":"42","author":"Buteau","year":"1999","journal-title":"Diabetologia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-0323","article-title":"Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets","volume":"144","author":"Farilla","year":"2003","journal-title":"Endocrinology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.regpep.2010.05.008","article-title":"Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes","volume":"164","author":"Werner","year":"2010","journal-title":"Regul peptides"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.21052","article-title":"[New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus((R)) tablets), an oral GLP-1 receptor agonist]","volume":"157","author":"Miyasaka","year":"2022","journal-title":"Nihon yakurigaku zasshi Folia pharmacologica Japonica"},{"key":"B25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.diabres.2008.09.037","article-title":"Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea","volume":"83","author":"Gao","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2541","article-title":"Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia)","volume":"30","author":"Yu Pan","year":"2014","journal-title":"Diabetes\/metabolism Res Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13340","article-title":"Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial","volume":"20","author":"Chen","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.342","article-title":"Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study","volume":"5","author":"Zhang","year":"2019","journal-title":"Obes Sci Pract"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14163","article-title":"Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial","volume":"22","author":"Gao","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B30","doi-asserted-by":"publisher","first-page":"154415","DOI":"10.1016\/j.metabol.2020.154415","article-title":"Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes","volume":"114","author":"Grespan","year":"2021","journal-title":"Metabolism: Clin Exp"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1914","article-title":"DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks","volume":"33","author":"Buse","year":"2010","journal-title":"Diabetes Care"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1230","article-title":"Methods for evaluation of medication adherence and persistence using automated databases","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiology Drug Saf"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01382-9","article-title":"Real-world evaluation of GLP-1 receptor agonist therapy persistence, adherence and therapeutic inertia among obese adults with type 2 diabetes","volume":"14","author":"Palanca","year":"2023","journal-title":"Diabetes therapy: research Treat Educ Diabetes related Disord"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002517","article-title":"Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK","volume":"10","author":"Weiss","year":"2022","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01053-7","article-title":"Semaglutide once-weekly persistence and adherence versus other GLP-1 RAs in patients with type 2 diabetes in a US real-world setting","volume":"12","author":"Uzoigwe","year":"2021","journal-title":"Diabetes therapy: research Treat Educ Diabetes related Disord"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01091","article-title":"Single-dose metformin enhances bile acid-induced glucagon-like peptide-1 secretion in patients with type 2 diabetes","volume":"102","author":"Bronden","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2014.08.004","article-title":"Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity","volume":"106","author":"Wu","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0637-5","article-title":"Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells","volume":"48","author":"Kappe","year":"2013","journal-title":"J Gastroenterol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1044030","article-title":"Gut microbiota is correlated with gastrointestinal adverse events of metformin in patients with type 2 diabetes","volume":"13","author":"Huang","year":"2022","journal-title":"Front Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13869","article-title":"Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids","volume":"22","author":"Sansome","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.141319","article-title":"Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions","volume":"18","author":"Singh","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(94)01430-9","article-title":"Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences","volume":"358","author":"Wei","year":"1995","journal-title":"FEBS Lett"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.6326-11.2012","article-title":"The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors","volume":"32","author":"Dickson","year":"2012","journal-title":"J Neurosci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0474","article-title":"Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans","volume":"60","author":"Nauck","year":"2011","journal-title":"Diabetes"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2022.0029","article-title":"Tirzepatide - a dual GIP\/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes","volume":"73","author":"Nowak","year":"2022","journal-title":"Endokrynologia Polska"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01434-6","article-title":"Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives","volume":"440","author":"Meier","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.5.1187","article-title":"One week\u2019s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci","article-title":"Anaphylaxis to long-acting release exenatide","volume":"28","author":"Ornelas","year":"2018","journal-title":"J investigational allergology Clin Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0720","article-title":"Allergic reaction to exenatide and lixisenatide but not to liraglutide: unveiling anaphylaxis to glucagon-like peptide 1 receptor agonists","volume":"42","author":"Shamriz","year":"2019","journal-title":"Diabetes Care"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-023-06484-8","article-title":"Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study","volume":"33","author":"Jensen","year":"2023","journal-title":"Obes Surg"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.995646","article-title":"Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain","volume":"13","author":"Garcia de Lucas","year":"2022","journal-title":"Front Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1347684\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T08:47:09Z","timestamp":1709887629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1347684\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":52,"alternative-id":["10.3389\/fendo.2024.1347684"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1347684","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]},"article-number":"1347684"}}